Literature DB >> 20168238

Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening.

Feras M Hantash1, Dana G Goos, David Tsao, Franklin Quan, Arlene Buller-Burckle, Mei Peng, Michael Jarvis, Weimin Sun, Charles M Strom.   

Abstract

PURPOSE: Fragile X syndrome is caused by expansion and subsequent methylation of a CGG trinucleotide repeat in the FMR1 5'-untranslated region. Southern blot analysis is typically required to determine expansion size for triplet repeat lengths >200. We describe a triplet-primed polymerase chain reaction-based method using automated capillary electrophoresis detection for qualitative assessment of expanded CGG repeats.
METHODS: The assay uses triplet-primed polymerase chain reaction in combination with GC-melting reagents and substitution of 7-deaza-2-deoxyGTP for dGTP. Amplicons are resolved by capillary electrophoresis.
RESULTS: A distinctive pattern of tapering or "stutter" polymerase chain reaction amplification was evident on capillary electrophoresis in male and female patients harboring all expanded allele lengths examined (up to 2000 CGG repeats) and could be used to differentiate normal, intermediate, premutation, and full mutation alleles. Full mutation alleles exhibited an additional late-migrating amplicon on capillary electrophoresis. Mixing experiments demonstrated sensitivity as low as 1% for detection of the full mutation allele. In a 1275-sample concordance study against our existing polymerase chain reaction platform (with Southern blot analysis for repeat lengths ≥55), the triplet-primed polymerase chain reaction method exhibited 100% concordance for normal, intermediate, expanded, and full mutation alleles. This method also detected the full mutation alleles in DNA isolated from blood spots.
CONCLUSION: This assay provides an accurate assessment of FMR1 repeat status and holds promise for use in carrier and newborn screening. The method distinguishes normal homozygous females from full mutation carrying females. Although the method is not useful for accurate sizing, it supplements the classic polymerase chain reaction method and results in significant reduction in the number of Southern blot analyses required to be performed in the laboratory to accurately assess the FMR1 genotype in all individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20168238     DOI: 10.1097/GIM.0b013e3181d0d40e

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  28 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Advanced technologies for the molecular diagnosis of fragile X syndrome.

Authors:  Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2015-10-21       Impact factor: 5.225

3.  A dual-mode single-molecule fluorescence assay for the detection of expanded CGG repeats in Fragile X syndrome.

Authors:  Brian Cannon; Cynthia Pan; Liangjing Chen; Andrew G Hadd; Rick Russell
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

4.  Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.

Authors:  Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-22       Impact factor: 3.568

5.  A novel assay for evaluating fragile X locus repeats.

Authors:  Karl Adler; J Kent Moore; Galina Filippov; Shaoping Wu; Jon Carmichael; Mack Schermer
Journal:  J Mol Diagn       Date:  2011-07-26       Impact factor: 5.568

6.  FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles.

Authors:  David E Godler; Howard R Slater; Quang M Bui; Michele Ono; Freya Gehling; David Francis; David J Amor; John L Hopper; Randi Hagerman; Danuta Z Loesch
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

7.  The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge.

Authors:  François Rousseau; Yves Labelle; Johanne Bussières; Carmen Lindsay
Journal:  Clin Biochem Rev       Date:  2011-08

8.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

Review 9.  Fragile X and X-linked intellectual disability: four decades of discovery.

Authors:  Herbert A Lubs; Roger E Stevenson; Charles E Schwartz
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

Review 10.  Fragile X syndrome: A review of clinical management.

Authors:  Reymundo Lozano; Atoosa Azarang; Tanaporn Wilaisakditipakorn; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.